NEW YORK (GenomeWeb) – Agilent Technologies announced today that its Dako PD-L1 IHC 28-8 pharmDx test, a companion diagnostic for Bristol-Myers Squibb's cancer drug Opdivo (nivolumab), has has received an expanded CE mark for use in Europe.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.